Ratings by JPMorgan (Chris Schott)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 2/23/2023 | Merck | MRK | Maintain | Overweight (N/A) |
|
Details | ||
| 2/21/2023 | Elanco Animal Health | ELAN | Maintain | Neutral (N/A) |
|
Details | ||
| 2/7/2023 | IDEXX Laboratories | IDXX | Maintain | Overweight (N/A) |
|
Details | ||
| 2/6/2023 | Regeneron Pharma | REGN | Maintain | Overweight (N/A) |
|
Details | ||
| 2/1/2023 | Pfizer | PFE | Maintain | Neutral (N/A) |
|
Details | ||
| 1/30/2023 | IDEXX Laboratories | IDXX | Maintain | Overweight (N/A) |
|
Details | ||
| 1/20/2023 | Regeneron Pharma | REGN | Upgrade | Overweight (Neutral) |
724.55 (826.97) |
14.14% | Details | |
| 12/16/2022 | Teva Pharma | TEVA | Maintain | Underweight (N/A) |
|
Details | ||
| 12/16/2022 | Perrigo Co. | PRGO | Maintain | Overweight (N/A) |
|
Details | ||
| 12/16/2022 | Elanco Animal Health | ELAN | Maintain | Neutral (N/A) |
|
Details | ||
| 12/16/2022 | Coherus Biosciences | CHRS | Maintain | Neutral (N/A) |
|
Details | ||
| 12/16/2022 | Regeneron Pharma | REGN | Maintain | Neutral (N/A) |
|
Details | ||
| 12/16/2022 | Merck | MRK | Maintain | Overweight (N/A) |
|
Details | ||
| 12/16/2022 | Gilead Sciences | GILD | Maintain | Overweight (N/A) |
|
Details | ||
| 12/16/2022 | Biogen | BIIB | Maintain | Neutral (N/A) |
|
Details | ||
| 12/16/2022 | Abbvie | ABBV | Maintain | Overweight (N/A) |
|
Details | ||
| 12/14/2022 | Eli Lilly | LLY | Maintain | Overweight (N/A) |
|
Details | ||
| 11/15/2022 | Viatris | VTRS | Maintain | Neutral (N/A) |
|
Details | ||
| 11/14/2022 | Heska Corp. | HSKA | Maintain | Overweight (N/A) |
|
Details | ||
| 11/14/2022 | Coherus Biosciences | CHRS | Maintain | Neutral (N/A) |
|
Details | ||
| 11/14/2022 | EQRx, Inc. | EQRX | Downgrade | Underweight (Neutral) |
3.89 (1.81) |
-53.47% | Details | |
| 11/14/2022 | Teva Pharma | TEVA | Downgrade | Underweight (Neutral) |
9.40 (8.76) |
-6.81% | Details | |
| 11/9/2022 | Elanco Animal Health | ELAN | Maintain | Neutral (N/A) |
|
Details | ||
| 11/8/2022 | Perrigo Co. | PRGO | Maintain | Overweight (N/A) |
|
Details | ||
| 10/28/2022 | Gilead Sciences | GILD | Maintain | Overweight (N/A) |
|
Details | ||
| 10/24/2022 | Amgen | AMGN | Maintain | Neutral (N/A) |
|
Details | ||
| 10/17/2022 | Zoetis Inc. | ZTS | Maintain | Overweight (N/A) |
|
Details | ||
| 10/17/2022 | IDEXX Laboratories | IDXX | Maintain | Overweight (N/A) |
|
Details | ||
| 10/17/2022 | Heska Corp. | HSKA | Maintain | Overweight (N/A) |
|
Details | ||
| 10/17/2022 | Elanco Animal Health | ELAN | Maintain | Neutral (N/A) |
|
Details | ||
| 10/11/2022 | Pfizer | PFE | Maintain | Neutral (N/A) |
|
Details | ||
| 10/4/2022 | Gilead Sciences | GILD | Upgrade | Overweight (Neutral) |
62.32 (80.97) |
29.93% | Details | |
| 9/30/2022 | Biogen | BIIB | Maintain | Neutral (N/A) |
|
Details | ||
| 9/26/2022 | Viatris | VTRS | Maintain | Neutral (N/A) |
|
Details | ||
| 9/8/2022 | Regeneron Pharma | REGN | Maintain | Neutral (N/A) |
|
Details | ||
| 8/16/2022 | EQRx, Inc. | EQRX | New Coverage | Neutral (N/A) |
4.82 (1.81) |
-62.45% | Details | |
| 8/16/2022 | Elanco Animal Health | ELAN | Downgrade | Neutral (Overweight) |
20.08 (8.93) |
-55.53% | Details | |
| 8/2/2022 | Regeneron Pharma | REGN | New Coverage | Neutral (N/A) |
581.69 (826.97) |
42.17% | Details | |
| 8/2/2022 | Gilead Sciences | GILD | New Coverage | Neutral (N/A) |
59.75 (62.32) |
4.3% | Details | |
| 8/2/2022 | Biogen | BIIB | New Coverage | Neutral (N/A) |
215.06 (270.25) |
25.66% | Details | |
| 8/2/2022 | Amgen | AMGN | New Coverage | Neutral (N/A) |
247.47 (238.48) |
-3.63% | Details | |
| 7/28/2022 | Bausch Health Companies | BHC | Downgrade | Neutral (Overweight) |
8.68 (7.47) |
-13.94% | Details | |
| 7/18/2022 | Elanco Animal Health | ELAN | Maintain | Overweight (N/A) |
|
Details | ||
| 6/13/2022 | Bausch Health Companies | BHC | New Coverage | Overweight (N/A) |
8.38 (8.68) |
3.58% | Details | |
| 4/14/2022 | Royalty Pharma | RPRX | Upgrade | Overweight (Neutral) |
41.81 (37.07) |
-11.34% | Details | |
| 3/7/2022 | Coherus Biosciences | CHRS | Downgrade | Neutral (Overweight) |
11.56 (6.42) |
-44.46% | Details | |
| 3/1/2022 | Viatris | VTRS | Maintain | Neutral (N/A) |
|
Details | ||
| 2/23/2022 | Heska Corp. | HSKA | Maintain | Overweight (N/A) |
|
Details | ||
| 1/28/2022 | Merck | MRK | Maintain | Overweight (N/A) |
|
Details | ||
| 1/18/2022 | Horizon Therapeutics | HZNP | Maintain | Overweight (N/A) |
|
Details | ||
| 1/18/2022 | Abbvie | ABBV | Maintain | Overweight (N/A) |
|
Details | ||
| 9/21/2021 | Bausch Health Companies | BHC | Maintain | Overweight (N/A) |
|
Details | ||
| 9/13/2021 | Pfizer | PFE | Maintain | Neutral (N/A) |
|
Details | ||
| 8/12/2021 | Perrigo Co. | PRGO | Maintain | Overweight (N/A) |
|
Details | ||
| 8/5/2021 | Horizon Therapeutics | HZNP | Maintain | Overweight (N/A) |
|
Details | ||
| 8/2/2021 | IDEXX Laboratories | IDXX | Maintain | Overweight (N/A) |
|
Details | ||
| 8/2/2021 | Abbvie | ABBV | Maintain | Overweight (N/A) |
|
Details | ||
| 6/24/2021 | Eli Lilly | LLY | Maintain | Overweight (N/A) |
|
Details | ||
| 6/16/2021 | Elanco Animal Health | ELAN | Maintain | Overweight (N/A) |
|
Details | ||
| 6/15/2021 | Eli Lilly | LLY | Maintain | Overweight (N/A) |
|
Details | ||
| 6/15/2021 | Organon & Co. | OGN | New Coverage | Neutral (N/A) |
30.28 (22.24) |
-26.55% | Details | |
| 3/2/2021 | Eli Lilly | LLY | Maintain | Overweight (N/A) |
|
Details | ||
| 3/2/2021 | Viatris | VTRS | Downgrade | Neutral (Overweight) |
14.85 (9.53) |
-35.82% | Details | |
| 2/22/2021 | Abbvie | ABBV | Maintain | Overweight (N/A) |
|
Details | ||
| 1/29/2021 | Heska Corp. | HSKA | New Coverage | Overweight (N/A) |
172.71 (93.31) |
-45.97% | Details | |
| 1/29/2021 | IDEXX Laboratories | IDXX | New Coverage | Overweight (N/A) |
465.18 (488.14) |
4.94% | Details | |
| 11/16/2020 | Pfizer | PFE | Maintain | Neutral (N/A) |
|
Details | ||
| 10/16/2020 | Merck | MRK | Maintain | Overweight (N/A) |
|
Details | ||
| 10/16/2020 | Eli Lilly | LLY | Maintain | Overweight (N/A) |
|
Details | ||
| 10/16/2020 | Bristol-Myers Squibb Co. | BMY | Maintain | Overweight (N/A) |
|
Details | ||
| 10/16/2020 | Abbvie | ABBV | Maintain | Overweight (N/A) |
|
Details | ||
| 9/9/2020 | Horizon Therapeutics | HZNP | New Coverage | Overweight (N/A) |
71.53 (109.00) |
52.38% | Details | |
| 8/24/2020 | Bausch Health Companies | BHC | Maintain | Overweight (N/A) |
|
Details | ||
| 7/13/2020 | Repros Therapeutics | RPRX | New Coverage | Neutral (N/A) |
48.36 (37.07) |
-23.35% | Details | |
| 6/1/2020 | Pfizer | PFE | Maintain | Neutral (N/A) |
|
Details | ||
| 5/19/2020 | Mallinckrodt plc | MNK | Downgrade | Underweight (Neutral) |
3.13 (7.81) |
149.52% | Details | |
| 5/19/2020 | TherapeuticsMD | TXMD | Downgrade | Neutral (Overweight) |
1.17 (3.49) |
198.29% | Details | |
| 5/12/2020 | Abbvie | ABBV | New Coverage | Overweight (N/A) |
87.90 (158.25) |
80.03% | Details | |
| 3/24/2020 | Perrigo Co. | PRGO | Upgrade | Overweight (Neutral) |
42.13 (34.61) |
-17.85% | Details | |
| 2/20/2020 | Pacira Pharmaceuticals | PCRX | Maintain | Neutral (N/A) |
|
Details | ||
| 12/18/2019 | Eli Lilly | LLY | Maintain | Overweight (N/A) |
|
Details | ||
| 12/12/2019 | Bausch Health Companies | BHC | Upgrade | Overweight (Neutral) |
29.24 (7.47) |
-74.45% | Details | |
| 11/12/2019 | Amneal Pharmaceuticals | AMRX | Downgrade | Underweight (Neutral) |
1.61 (5178.30) |
321533.54% | Details | |
| 11/12/2019 | Teva Pharma | TEVA | Upgrade | Neutral (Underweight) |
9.30 (8.76) |
-5.81% | Details | |
| 5/3/2019 | Bristol-Myers Squibb Co. | BMY | New Coverage | Overweight (N/A) |
46.88 (68.20) |
45.48% | Details | |
| 3/12/2019 | Eli Lilly | LLY | New Coverage | Overweight (N/A) |
126.70 (337.65) |
166.5% | Details | |
| 12/11/2018 | Pfizer | PFE | Downgrade | Neutral (Overweight) |
44.40 (39.99) |
-9.93% | Details | |
| 10/15/2018 | Zoetis Inc. | ZTS | Upgrade | Overweight (Neutral) |
87.00 (165.04) |
89.7% | Details | |
| 10/15/2018 | Elanco Animal Health | ELAN | New Coverage | Overweight (N/A) |
32.39 (8.93) |
-72.43% | Details | |
| 9/26/2018 | Eli Lilly | LLY | New Coverage | Overweight (N/A) |
105.59 (126.70) |
19.99% | Details |
